Expert opinions on immunotherapy for patients with colorectal cancer

Affiliations

¹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, P. R. China.
² Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P. R. China.
³ Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, 100142, P. R. China.
⁴ Department of Medical Oncology, Tongji University Shanghai East Hospital, Shanghai, 200120, P. R. China.
⁵ Department of Surgical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, P. R. China.

Editorial

Feng Wang et al. Cancer Commun (Lond). 2020 Oct.

. 2020 Oct;40(10):467-472.

doi: 10.1002/cac2.12095. Epub 2020 Sep 18.

¹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, P. R. China.
² Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P. R. China.
³ Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, 100142, P. R. China.
⁴ Department of Medical Oncology, Tongji University Shanghai East Hospital, Shanghai, 200120, P. R. China.
⁵ Department of Surgical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, P. R. China.

No abstract available

References

1. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16(6):361‐75. - PMC - PubMed
1. Wu T, Wu X, Wang HY, Chen L. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun (Lond) 2019;39(1):21. - PMC - PubMed
1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD‐1 Blockade in Tumors with Mismatch‐Repair Deficiency. N Engl J Med 2015;372(26):2509‐20. - PMC - PubMed
1. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II Open‐Label Study of Pembrolizumab in Treatment‐Refractory, Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer: KEYNOTE‐164. J Clin Oncol 2020;38(1):11‐9. - PMC - PubMed
1. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H‐J, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair‐deficient or microsatellite instability‐high colorectal cancer (CheckMate 142):an open‐label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182‐91. - PMC - PubMed